Patents by Inventor Nicholas S. Caron

Nicholas S. Caron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Allele-specific therapy for Huntington disease haplotypes
    Patent number: 10731160
    Abstract: The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847. Specific oligomer sequences are also provided.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: August 4, 2020
    Assignee: The University of British Columbia
    Inventors: Amber L. Southwell, Christopher Kay, Michael R. Hayden, Nicholas S. Caron
  • ALLELE-SPECIFIC THERAPY FOR HUNTINGTON DISEASE HAPLOTYPES
    Publication number: 20200199595
    Abstract: The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847. Specific oligomer sequences are also provided.
    Type: Application
    Filed: January 7, 2020
    Publication date: June 25, 2020
    Applicant: The University of British Columbia
    Inventors: Amber L. Southwell, Christopher Kay, Michael R. Hayden, Nicholas S. Caron
  • Allele-specific therapy for huntington disease haplotypes
    Patent number: 10533172
    Abstract: The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847. Specific oligomer sequences are also provided.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: January 14, 2020
    Assignee: The University of British Columbia
    Inventors: Amber L. Southwell, Christopher Kay, Michael R. Hayden, Nicholas S. Caron
  • ALLELE-SPECIFIC THERAPY FOR HUNTINGTON DISEASE HAPLOTYPES
    Publication number: 20170253877
    Abstract: The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847. Specific oligomer sequences are also provided.
    Type: Application
    Filed: September 18, 2015
    Publication date: September 7, 2017
    Applicant: The University of British Columbia
    Inventors: Amber L. Southwell, Christopher Kay, Michael R. Hayden, Nicholas S. Caron